The vendor that used to be the customer: Pivot Path’s $27M spinout story

Every pharma CIO has sat through the same vendor pitch: a platform built by people who understand the idea of a regulated environment, but who have never actually owned a deviation, fronted an inspection, or explained a missing signature to an FDA auditor. Pivot Path breaks that pattern by inverting it. The company didn’t set out to build software for pharma companies — it set out to run pharmacovigilance, validation, and manufacturing IT inside Strides Pharma’s own regulated operations, and only became a vendor once its internal tools had already survived the audits, inspections, and quality reviews that every one of its future customers would eventually put it through.

Now spun out as an independent company, Pivot Path serves more than 70 pharma companies across five continents, generates INR 147 crore in revenue, is already profitable, and just raised INR 100 crore (roughly $12M) from Ascent Capital at a INR 230 crore valuation — around $27M.

For CIOs and CISOs in regulated industries, the funding round is the least interesting part of this story. What matters is the lineage: Pivot Path’s products, from audit-trail monitoring to pharmacovigilance case processing, weren’t designed by a vendor guessing what pharma companies need. They were built to solve problems Pivot Path’s own team was accountable for inside Strides Pharma’s plants, labs, and quality functions — then hardened for external customers. In an industry where “the vendor has never actually run GxP operations” is a common and reasonable objection, being the customer first is the entire pitch.

We sat down with Shashidhar KL, CEO of Pivot Path, to understand why the spinout happened now, what genuinely had to change to sell internal tooling externally, and why he believes the operator-built model beats both buying off-the-shelf software and building in-house — even for large pharma companies with the resources to do either.

From cost center to category

Strides Pharma didn’t need to spin Pivot Path out. It could have run it as an internal function indefinitely. Shashidhar frames the decision as recognition rather than separation: by the time the demerger happened, functions like validation, quality, pharmacovigilance, manufacturing IT, and regulatory technology had matured into repeatable practices with their own methods and their own accountability for outcomes — “those are the characteristics of a business rather than a cost centre,” he says, “and running it as a cost centre was starting to cap what it could become.”

There’s also a structural reason the problem existed in the first place. Strides Pharma wasn’t one operation — it was API, CDMO, and finished dosage formulation businesses spread across India, Africa, the U.S., and Europe, assembled through years of acquisitions. As Shashidhar puts it, an acquisition “hands you several” quality systems and ways of working, “each qualified under different assumptions and each convinced its own way is the correct one.” Making that heterogeneity run on common systems and common controls was Pivot Path’s own operational problem years before it became a commercial product — which is exactly the kind of scar tissue an outside vendor doesn’t have.

The market timing mattered too. Pharma companies are modernizing against tighter regulatory expectations and more distributed supply chains, and according to Shashidhar, they’re increasingly unwilling to buy from a vendor that “must learn GxP” on the customer’s dime.

What actually had to change to sell internal tools externally

This is where the interview gets genuinely useful for any CIO evaluating a build-vs-buy decision in a regulated environment. Turning an internal platform into a commercial one, Shashidhar says, required four re-architectures — three technical, one not:

– Isolation: An internal platform can assume one quality system and one governance model. A commercial one can’t. Pivot Path now isolates each customer’s data across application, data, document, vector, and access layers, with customers choosing deployment region, while the underlying environment stays in continuous validation rather than being re-qualified per customer.
– Configurability: Internal tools encode one company’s process — efficient until a second customer shows up. Workflows, approval chains, risk matrices, and reporting had to become configuration, not code. In AnomIQ, the company’s audit-trail monitoring product, detection rules are customer-configured and versioned, which Shashidhar notes is also what makes the system’s behavior explainable to that customer’s auditor.
– Governance as an environment property, not an app feature: Retrieval grounded in customer-owned content, versioning, traceability, logging, and human review had to move out of individual applications and become properties of the shared layer everything runs on — PivotAI inside PivotOS, Pivot Path’s validated GxP cloud environment. Practically, that means a new application launches on an already-qualified stack instead of starting from zero.
– Documentation as product, not paperwork: Internal software never has to explain itself because the people using it built it. External software does. Validation deliverables, intended-use documentation, and support models had to become deliverables in their own right — which Shashidhar argues “is not paperwork wrapped around the product. For a quality organisation it is a large part of the product.”

The uniqueness case: features a vendor would never think to build

Asked for an example of something in the platform a traditional software vendor simply wouldn’t have built, Shashidhar didn’t point to an AI feature — he pointed to paper.

NoteIQ, Pivot Path’s document management platform, treats hard-copy management as a first-class event. That sounds backward for a system whose entire purpose is getting off paper. But as Shashidhar explains, a controlled document that’s been printed still exists — on a shop floor, in a QC lab, at a line clearance — and at an inspection, “someone will ask how many copies were issued, to whom, and whether they came back.” So in NoteIQ, issuing a copy is recorded, reprints carry their own traceability, and circulation is accounted for. It’s a requirement that’s easy to miss on paper (literally) and obvious the moment you’ve had to answer for a stray printed page during an audit.

The second example is closed-loop action inside AnomIQ. A detected anomaly sitting in a report is worth far less than the same finding acted on before a batch moves. When a detection matches a customer-configured, versioned rule, AnomIQ can trigger a routed task, an alert, or a protective hold on a batch in SAP so it can’t advance to production — deterministic and fail-safe by design, Shashidhar is careful to note, not the AI exercising judgment. Releasing the hold stays with a qualified human reviewer.

“What both have in common,” he says, “is that neither came from a requirements workshop… If you have carried the consequence of a missing control yourself, you tend to specify the control before anybody asks for it.”

Where the ROI is real — and how to tell it from an AI theater

For CIOs weary of AI pitches that lead with model quality instead of business outcomes, Shashidhar offers a blunt filter: ask what number will move, who owns it, and what it was before. If the answer is “the model is state of the art” or “the programme builds AI readiness,” a technology purchase is being dressed up as transformation.

By his account, the biggest measurable returns today sit in quality and compliance — traditionally the most document-heavy, qualified-effort-intensive work in a pharma operation:

– AnomIQ cuts manual audit-trail review effort by 60–70% and detects issues roughly 85% faster, shifting review from periodic sampling to continuous monitoring.
– InvestigationIQ removes an estimated 40–60% of investigation cycle time.
– NovaVigil, the pharmacovigilance platform, delivers roughly 63% faster case reviews with about 50% lower FTE overhead across literature monitoring and intake — notable given the company’s PV unit already handles 35,000+ ICSRs a year across 400+ molecules.
– CSA-based validation, replacing document-everything CSV, has been applied to 200+ validated RPAs and 10,000+ documents.

Shashidhar is candid that AI maturity is, counterintuitively, the least important of the three forces reshaping pharma tech investment right now — behind regulation and supply chain complexity. Model capability, he argues, “stopped being the constraint a while ago.” The real bottleneck is that the context an answer depends on — which product, site, batch, supplier, or prior deviation — is scattered across a dozen disconnected systems. “That is a data engineering problem before it is an AI problem,” he says, “and it is unglamorous, which is why it is under-invested.”

The build-vs-buy-vs-partner answer, from someone who’s done all three

For CIOs and CTOs at large pharma companies with the resources to build this themselves, Shashidhar’s answer isn’t “you can’t.” It’s that most assessments underestimate what building actually includes. The model or workflow engine, he says, is the small part — the durable, permanent cost is validation, governance, documentation, security, and evidence, kept current as regulations and internal procedures evolve. That’s not a project cost; it’s an operating commitment that competes for the same specialized people a pharma company needs on its actual products.

His framing for the decision isn’t build versus buy at all — it’s which capabilities an organization intends to own permanently, validation burden included. Genuinely differentiating, highly specific processes: build them. Mature, commoditized categories: buy the leading product. And the large middle ground — regulated, evidence-heavy, still evolving, common across the industry rather than unique to any one company — is where partnering, in his view, earns its place. Compliance documentation, audit-trail review, validation, and case processing all sit squarely in that middle.

What’s next

Pivot Path’s five-year plan keeps pharma as the core but shifts the internal mix from a services business with products inside it to a technology business with operations feeding it. The piece Shashidhar is most focused on is a knowledge graph spanning quality, manufacturing, safety, and supply chain — the infrastructure that would let an agent connect a deviation pattern at one site to a supplier change and an emerging safety signal, grounded in validated enterprise data rather than a general model’s guesswork.

For CIOs weighing AI vendors in regulated industries, Pivot Path’s pitch is less about any single product and more about provenance: a platform built by people who had to live with the consequences of getting it wrong first — and then had to prove that to a customer’s quality team before they ever proved it to IT.